Research.Patient.info
Hormone Receptor Positive HER-2 Negative Breast Cancer research hub
3 indexed studies · 3 currently recruiting
- recruitingPHASE2
Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer
This study looks at adding a drug called elacestrant to olaparib for patients with a certain type of advanced breast cancer and a BRCA gene change. It hopes to see if this combination works better than olaparib alone.
Germany - recruiting
Impact of Endocrine Therapy, Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and HER2- Breast Cancer
This study, called PEAK, looks at how different factors like menstrual cycles, hormone treatments, and specific tumour tests (PAM50, Ki67) affect decisions about breast cancer care. It focuses on a common type of breast cancer that's sensitive to hormones.
Germany - recruitingPHASE1, PHASE2
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
This study is testing a new medicine called EP0062 for advanced breast cancer. It aims to find the safest and most effective dose, both alone and with other standard treatments, for women whose cancer has specific features.
United States · Spain · United Kingdom